49 results
8-K
EX-99.1
ALLK
Allakos Inc
9 Aug 23
Allakos Provides Business Update and Reports Second Quarter 2023 Financial Results
4:08pm
research and development costs and clinical costs related to lirentelimab and a $2.9 million decrease in employee compensation, partially offset
8-K
EX-99.1
db80o
7 Nov 22
Allakos Provides Business Update and Reports Third Quarter 2022 Financial Results
4:06pm
424B5
j0mi lmwgjaxl354
19 Sep 22
Prospectus supplement for primary offering
7:32am
424B5
onrrjp0 z0oe7ksa
4 Aug 22
Prospectus supplement for primary offering
5:30pm
8-K
EX-99.1
lp26v7zv7t8oj2
4 Aug 22
Allakos Provides Business Update and Reports Second Quarter 2022 Financial Results
4:13pm
S-3
wd5i34w0v06
19 May 22
Shelf registration
4:53pm
S-3
er8pnl1gq61cf88og
19 May 22
Shelf registration
4:53pm
424B5
4ndvzzr599dtv
10 May 21
Prospectus supplement for primary offering
4:44pm